Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

Remicade comes as a powder. A healthcare professional mixes the powder with liquid to form a solution, which they give as an intravenous (IV) infusion. (This is an injection into a vein given over ...

Feb. 27, 2004 — Scheduled maintenance with infliximab reduced hospitalizations and improved healing compared with episodic dosing for patients with Crohn's disease, according to the results of a ...

HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...

LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year ...

In a double-blind multicenter study by Targan et al., [50] 108 patients with active, refractory, moderate to severe CD (a mean CDAI score at baseline of approximately 300 despite treatment with ...

Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Home infusions of biologics appear to be a safe and cost-effective way to reduce the burden of ...

ATLANTA, Nov. 8, 2010 /PRNewswire/ -- Patients with active moderate to severe rheumatoid arthritis (RA) inadequately responding to either etanercept (Enbrel ®) or adalimumab (Humira ®) and who were ...

Many top drugmakers have faced allegations that they offered free services as kickbacks to doctors, and Johnson & Johnson is confronting those claims in a newly unsealed whistleblower lawsuit. In the ...

crohns disease Patients with Crohn disease were enrolled in a comparative cohort study that analyzed the outcomes of reference product infliximab vs biosimilar treatment. The effectiveness of ...